IOL Chemicals posts robust Q3 & 9M FY26 results, PBT up 39% YoY

Chemicals delivered improved efficiency and optimal capacity utilization, with EBIT rising 37% YoY

Apollo Hospitals reports robust Q3 earnings; profit after tax humps to Rs. 3,835 million

Revenue from operations rose to Rs. 23,637 million for the three months ended December 31, 2025

Veradermics completes enrollment in both Phase 3 male hair loss trials

The milestone means more than 1,000 men are now enrolled across both Phase 3 programs

SMS Pharmaceuticals posts strong Q3 with 29% PAT growth, full-year targets on track

The company’s EBITDA margin remained resilient above 20%

Biomica seals exclusive global license for groundbreaking microbiome cancer therapy

The therapy is currently completing Phase 1 clinical trials in renal cell carcinoma and non-small cell lung cancer

Mirum Pharmaceuticals bags Canadian nod for LIVMARLI to treat rare liver disorder

LIVMARLI’s new tablet form offers patients weighing 22 kg or more a convenient, one-tablet-per-dose option, complementing the existing 9.5 mg/ml oral solution

Wanbury reports explosive Q3 profit surge, signals strong growth ahead

Call it one of the most striking turnarounds in the Indian pharma sector this fiscal year

KIMS Hospitals crosses Rs. 1,000 crore quarterly revenue milestone

Alembic Pharmaceuticals gets USFDA nod for generic Parkinson's disease treatment tablets

The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Stalevo Tablets

Onchilles Pharma gets FDA green light for first-in-human trials of breakthrough cancer therapy

N17350 is the company’s first-in-class tumor-directed therapeutic, designed to harness the ELANE pathway